Current status of therapy for breast cancer worldwide and in Japan

Table 1 Phase III trial of nanoparticle albumin-bound paclitaxel (ABI-007) compared with polyethylated castor oil-based paclitaxel (standard paclitaxel) in women with breast cancer

Response	No. of patients/total No. ofpatients (%)		P
	ABI-007 (260 mg/m2)	Paclitaxel (175 mg/m2)
Complete and partial response
All patients	76/229 (33)	42/225 (19)	0.001
First-line therapy	41/97 (42)	24/89 (27)	0.029
Second-line or greater therapy	35/132 (27)	18/136 (13)	0.006
Prior anthracycline therapy
Adjuvant and/or metastatic	60/176 (34)	32/175 (18)	0.002
Metastatic only	31/115 (27)	18/130 (14)	0.010
Dominant metastatic organ site
Visceral	59/176 (34)	34/182 (19)	0.002
Non-visceral	17/50 (34)	8/43 (19)	NS
Age (yr)
< 65	68/199 (34)	36/193 (19)	< 0.001
≥ 65	8/30 (27)	6/32 (19)	NS

NS: Not significant statistically. Response rates (33% vs 19%, P = 0.001). (Source: Table 2 in reference 12).